Ivonescimab – the future of cancer therapy
Loading...
EJTCM_2025_8_2_Ficon.pdf (675.96 KB)
0009-0002-9903-7892 Date
2025-10-25
Journal Title
Journal ISSN
Volume Title
Publisher
Medical University of Gdańsk
Abstract
Ivonescimab is an innovative bispecific antibody targeting both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF-A). Through its dual mechanism (immunomodulatory and anti-angiogenic) it can effectively enhance the body’s immune response to cancer and inhibit the formation of new blood vessels, thereby slowing tumor growth. Clinical trials have demonstrated high efficacy of ivonescimab in treating nonsmall cell lung cancer (NSCLC). When combined with chemotherapy, ivonescimab significantly prolongs progression-free survival compared to pembrolizumab-based therapy. A higher response rate was also observed, with an acceptable safety profile. Results from the HARMONi-A and HARMONi-2 studies suggest that ivonescimab may become the proposed therapeutic regimen for first-line treatment. Further studies are underway to evaluate the broader potential of ivonescimab, as it may represent a promising option pending approval. The globalization of ivonescimab research increases the likelihood of its registration as the first anti-PD-1/anti-VEGF-A bispecific antibody, thus potentially revolutionizing cancer therapy. This article provides a concise summary of the mechanism of action and key clinical evidence supporting the use of Ivonescimab in NSCLC.
Description
Keywords
Citation
Ficoń W, Dobosz M, Całyniuk B. Ivonescimab – the future of cancer therapy. Eur J Transl Clin Med. 2025;8(2):81-85